-
Technology
-
Industry
-
Solutions
-
- ASSET MANAGEMENT
- CUSTOMER EXPERIENCE MANAGEMENT
- CYBER SECURITY
- DATA CENTER
- DOCUMENT MANAGEMENT
- ELECTRONIC DATA INTERCHANGE
- ENTERPRISE DATA MANAGEMENT
- ENTERPRISE RESOURCE PLANNING
- ENTERPRISE RISK MANAGEMENT
- ENTERPRISE-GRADE WEB DATA SOLUTIONS
- FACILITY MANAGEMENT
- FIELD SERVICE
- IDENTITY AND ACCESS MANAGEMENT
- INFRASTRUCTURE
- IT SERVICE MANAGEMENT
- MANAGED IT SERVICES
- PAYMENT AND CARD
- PROJECT MANAGEMENT
- SOFTWARE TESTING
- STORAGE
- VIDEO SOLUTIONS
- WORKFLOW
-
-
Platforms
-
Functions
- Leadership Perspectives
- Innovation Insights
- Research
- Magazines
- News
- CXO Awards
Richard T. Schumacher, CEO
In the sample preparation space, cell lysis is considered one of the most complex and critical steps in the preparation of samples for subsequent testing and research. Current methods for extracting biomolecules involve the use of chemicals, blades, metal beads, sound waves, or other mechanical methods. Although these methods appear to work, scientists are now beginning to realize that such harsh lysis methods can damage the biomolecules inside cells. These methods also result in sample loss and degradation, cross-contamination, shearing of molecules, and/or even limited applicability to different sample types (animal/plant and normal/diseased). Pressure, on the other hand, can be titrated to carefully break the cell membrane while minimizing impairment to the proteins and other cellular components, by exerting the exact level of pressure required for lysis (not too much and not too little). “While scientists have been well aware of the potential of pressure in theory, the risks of working with high pressure in the laboratory coupled with the lack of commercial instruments have for decades been major deterrents to the use of pressure in scientific research,” mentions Schumacher. This is where Massachusetts-based Pressure BioSciences has been able to turn the tables. Pioneering the game-changing concept of Pressure Cycling Technology (PCT), PBIO commercializes the use of pressure in labs for the high-quality preparation of research samples for biological studies.
PCT is a patented, enabling technology that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi) to safely, conveniently, and reproducibly control the actions of molecules in biological samples. Using PBIO’s powerful PCT platform, a researcher can manage pressure and turn it on and off, akin to controlling light with a switch.
PCT enables scientists to obtain accurate research outcomes faster
Moreover, a biological substance’s reaction time to pressure is instantaneous: by applying pressure to a cell, every biomolecule in or on the cell experiences the same pressure at that given moment as opposed to adding chemicals or using temperature, which usually takes a considerable amount of time to disseminate (equilibrate) throughout the cell. “As a result, PCT enables scientists to obtain more accurate research outcomes, much faster,” states Schumacher.
On the other hand, when a cell is lysed through mechanical or chemical means, because it is difficult for the scientist to control these methods, there may be a greater chance that the proteins in the cell could be damaged. Therefore, if a scientist aims to find and study a particular protein inside a cell, and is not using PCT for the cell lysis, the chances of successfully extracting the particular biomolecule from the cell may be reduced. “There can be as many as 10,000 different proteins in a cell, with each protein comprised of dozens to hundreds of amino acids, maybe more. So looking for a single amino acid abnormality on one protein out of up to 10,000 in a cell is like looking for a needle in the haystack. So scientists need the best possible tools available to help them in the discovery process. We believe that our PCT platform is one of those tools in proteomic research,” says Schumacher. As Pressure BioSciences’ PCT solution can minimize damage to the biomolecules in the cell, it also has the potential to increase the number of ‘needles’ in the ‘haystack’— thus increasing the possibility of discovery. To that point, PBIO’s Tag Line is “Discovery Starts with Sample Preparation™.” This aspect was further validated by Dr. Ruedi Aebersold, a renowned protein chemist, in a technical report for Nature Medicine (a leading scientific journal). Professor Aebersold wrote that the pressure cycling method not only helped his team increase the rate of successful protein extraction, but the higher-quality biomolecules also enhanced the outcomes of their studies.
Schumacher notes that throughout the biological sciences landscape, there are numerous enabling biotechnologies—“Our mission is to enable the enablers, with the goal to produce better outcomes for the scientist.” Striding in that direction, Pressure BioSciences recently acquired BaroFold Inc. to combine BaroFold’s patented high-pressure protein refolding technology with Pressure BioSciences’ PCT-enabled instrumentation. This new patented technology platform can control the refolding of misfolded recombinant proteins (many of which are used as therapeutic drug agents) into their native structures, as a way to improve and enhance their therapeutic activities. PBI has also recently received several patents for their unique Ultra Shear Technology (UST) platform, which has the potential to be used to make room stable, sterile dairy products (e.g., milk and liquid cheese). For the future, in addition to its current use in drug discovery, development, and design, Pressure BioSciences’ growth plan involves expanding PCT to areas such as agriculture, forensics and rape kit testing, non-invasive lipidomic screening of newborns, and more.
Pressure BioSciences Upcoming Investor Call to Discuss Recent Acquisition of Uncle Buds
Monday, February 19, 2024
SOUTH EASTON, Mass. -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, today announced that the Company will host a teleconference to discuss the recent strategic acquisition of natural health and wellness innovator Uncle Bud’s (“UB”) in an all-stock transaction. In particular, the Company will discuss its current, in-process move to new, more efficient manufacturing space; the integration plan of the Uncle Bud’s team and product offerings into PBIO; and the significant growth expected from new UltraShear processed nanoemulsion products, which are expected to catapult the Company’s total revenue by 5X to about $10M in 2024.
Teleconference Information
• Format: Company presentation followed by Q&A.
• Date: Monday, February 5, 2024. 4:30pm ET (US).
• Call-in Number: 888-267-2918 (code: 973092).
• Replay: PBIO.Replay.020524
Transaction Significance
• Transaction is expected to be immediately accretive and a major accelerator to PBIO’s top line revenue growth.
• Combined companies will be positioned to attract new growth investment, rapidly strengthen the balance sheet, accelerate PBIO’s path to profitability in 2024, and catalyze PBIO’s drive to uplist to NASDAQ/NYSE in 2024.
• UB leadership are experts in branding, spokesperson management, and online/retail multimedia marketing.
• UB will rapidly incorporate PBIO’s best-in-class Nano-CBD into renowned and successful CBD product lines.
• Senior management of UB/PBIO plan a dozen new nanoemulsion products for commercial release in 2024.
• UB already markets and sells many products in health & wellness that expand well beyond Hemp and CBD.
• UB continues building ongoing partnership with multi-Grammy award-winning Toni Braxton – highly successful marketing ambassador leaps to embrace combined PBIO/UB as continuing spokesperson.
• UB enjoys strong following for leading hemp and CBD products, in extensive variety of high profile news outlets and magazines online over many years: https://www.unclebudshemp.com/press/.
• UB currently boasts 70+ products, 865K on-line members, and enviable sales channels with leading large retailers.
Expected Financial Impact
• Acquisition combines existing momentum and ready market execution power of Uncle Bud’s, with revolutionary product breakthroughs in absorption and speed of action, enabled by PBIO’s UltraShear nanoemulsions platform.
• PBIO forecasts Uncle Bud’s $1.6 million 2023 revenue tripling to approximately $5 million in 2024.
• PBIO forecasts a 5-fold catapult forward in total Company revenues to approximately $10 million in 2024.
Pressure BioSciences Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing
Wednesday, February 21, 2024
Relocation Delivers Substantially Increased Manufacturing Space, Vastly Improved Operating Efficiencies, and Measurable Cost Savings for Unencumbered Growth through Multi-Year Expansion Plans
CANTON-- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, pharmaceutical, and other industries, today celebrated a significant milestone in its accelerating growth journey. The Company announced the consolidation of its Boston area operations, uniting all of its personnel into a single, cutting-edge facility designed to accommodate expanded R&D capabilities, advanced equipment development and production, formulation services, and contract manufacturing based on its patented Ultra Shear Technology (UltraShear™ or UST™) platform. The new building is currently being transformed into a state-of-the-art manufacturing facility.
Strategically located in the Boston suburb of Canton, MA, the new facility will provide PBIO with a larger, more efficient space to continue its groundbreaking work in high pressure nanotechnology platform development – and UltraShear technology in particular. The state-of-the-art facility is to be equipped with the latest modern utilities and amenities, and will house dedicated areas for R&D, equipment production, formulation services, and product manufacturing. This move, consolidating R&D with all other departments of the Company, aims to streamline and achieve new production efficiencies, reduce costs, and foster innovation within a collaborative and dynamic work environment.
Ken Micciche, PBIO’s Director of Business Development, commented: “We are very excited about the opportunities this consolidation and expansion presents. The move reinforces our commitment to accelerating development and production capabilities, delivering exceptional products and services, advancing the field of high-pressure nanotechnology, fostering collaborations with academic and industry partners, and supporting our expected explosive growth in the direct-to-consumer area, led by our newly acquired subsidiary company Uncle Bud’s Health & Wellness.”
Key Features of the New Facility:
Product Manufacturing Suites: PBIO is committed to meeting the increasing demand for its innovative nanoemulsion products, delivering breakthrough performance in fast and enhanced absorption of oil-soluble nutrients and therapeutics. The new facility will house several GMP-compliant contract manufacturing suites, equipped with the latest technology to ensure the efficient and precise production of high-quality products.
Advanced R&D Laboratory: PBIO is investing in the development of a cutting-edge research and development laboratory, where its team of highly trained and experienced experts will continue to push the boundaries of high-pressure nanotechnology. The laboratory will focus on developing groundbreaking solutions in nanoemulsions and other products for use in nutraceuticals, cosmeceuticals, pharmaceuticals, bioprocess, and other areas.
State-of-the-Art Equipment Manufacturing: The facility features a dedicated space for the manufacturing of advanced equipment and components incorporating state-of-the-art materials and designs used in the production of nanoemulsions and other products. This will enable PBIO to expand production capacity in UltraShear equipment installations, while maintaining stringent quality control and ensuring the total reliability of its products.
Formulation Services: With a focus on providing comprehensive solutions, PBIO currently offers limited formulation services to its UltraShear clients. With the Canton site’s expanded space and equipment, the Company’s Formulation Services are expected to expand and grow significantly, as it collaborates closely with customers to develop customized formulations tailored to their specific needs and requirements, spanning a diversity of major market applications from nutraceuticals to cosmeceuticals/skincare, pharmaceuticals, food & beverages, and natural, organic agrochemicals.
Demo Laboratory: A dedicated Demo Laboratory will showcase the Company’s cutting-edge UltraShear technology platform, allowing stakeholders to witness PBIO’s unique and far-reaching capabilities firsthand.
John Hollister, PBIO’s Director of Sales and Marketing, added: “Unlike our previous site, the new facility provides the needed environment for us to accomplish our aggressive commercial goals over the next few years. Our new facility – with its significantly increased manufacturing space – gives us the ability to expand manufacturing capabilities to meet the already increasing demand for our products. Our growth is no longer encumbered by our facilities.”
Company
Pressure BioSciences
Management
Richard T. Schumacher, CEO
Description
A life sciences company that pioneered the Pressure Cycling Technology
(PCT)
